UROV - Urovant Has Upside Potential Heading Into Vibegron's PDUFA Later This Year

Urovant Sciences (UROV) is a stock that just recently came onto my radar when I read Terry Chrisomalis' article here on Seeking Alpha. That led me to doing my own research and discounted cash flow analysis, and I came to much the same conclusion as Terry. Although nothing is ever a certainty with biopharma companies, any way I ran, the numbers suggested substantial upside potential for Urovant. In this article, I'll highlight some important points about the company and the overactive bladder market that plays an important role in my modeling and expectations for the

Read more ...